Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting

Clinical Infectious Diseases

Volumn 52, Issue 2, 2011, Pages 264-270

  Van Zyl, G U ^a   Preiser, W ^a   Potschka, S ^b   Lundershausen, A T ^b   Haubrich, R ^c   Smith, D ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ACCURACY; AGED; ALGORITHM; ARTICLE; CELL COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT MONITORING; PATIENT SELECTION; PLASMA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PLASMA; RNA, VIRAL; SPECIMEN HANDLING; VIRAL LOAD; YOUNG ADULT;

EID: 79951845518     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq084     Document Type: Article

References (29)

1. UNAIDS. Report on the global AIDS epidemic. Geneva, 2008. Available from http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/ default.asp. Accessed 7 September 2010.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults adolescents: recommendations for a public health approach, 2010 revision. Geneva: WHO, 2010. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed 13 July 2010.
3. Boulle A, Bock P, Osler M, et al. Antiretroviral and therapy early mortality in South Africa. Bull World Health Organ 2008;86:678-87.
4. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44.
5. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009;49:454-62.
6. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resourcelimited setting. BMC Infect Dis 2008;8:89.
7. Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clin Infect Dis 2009;49:463-5.
8. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22:1971-7.
9. Keiser O, MacPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009;14:1220-5.
10. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-34.
11. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009;12:11.
12. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009;49:1928-35.
13. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 2008;22:2210-2.
14. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-97. (Pubitemid 351706742)
15. National Department of Health, South Africa. Clinical guidelines for the management of HIV and AIDS in adults and adolescents, 2010. Available at: http://www.sanac.org.za/documents/2010%20Adult% 20ART%20Guidelines.pdf. Accessed 7 September 2010.
16. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
17. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005;352:1873-83. (Pubitemid 40627813)
18. Klausner JD, Grant RM, Kent CK. Detection of acute HIV infections. N Engl J Med 2005;353:631-3.
19. Pilcher CD, Eron JJ, Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004;113:937-45. (Pubitemid 38544111)
20. Smith DM, May SJ, Perez-Santiago J, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 2009;23:2151-8.
21. May S, Gamst A, Haubrich R, Benson C, Smith DM. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr 2010;53:194-201.
22. Usdin M, Guillerm M, Calmy A. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J Infect Dis 2010;201: S73-7.
23. Drosten C, Panning M, Drexler JF, et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem 2006;52:1258-66. (Pubitemid 43956016)
24. Alvarez-Munoz MT, Zaragoza-Rodriguez S, Rojas-Montes O, et al. High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions. Arch Med Res 2005;36:382-6. (Pubitemid 40798393)
25. Andreotti M, Pirillo M, Guidotti G, et al. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol 2010;47:4-7.
26. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009;49:976-81.
27. van Deursen P, Oosterlaken T, Andre P, et al. Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS easyQ HIV-1 v2.0. J Clin Virol 2010;47:120-5.
28. Mbida AD, Sosso S, Flori P, et al. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood plasma spot specimens collected in 2 rural dispensaries in Cameroon. J Acquir Immune Defic Syndr 2009;52:9-16.
29. Marconi A, Balestrieri M, Comastri G, et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 2009;15:93-7.